fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Dow, S&P & AI Stocks Soar To Record Highs As Interest Rates Jump This Week – $AAPL $BFRG $DECK $INDP $LTRN $NVDA Rise!

By John F. Heerdink, Jr.
Quote of the Day: “A man should always consider how much he has more than he wants.” – Joseph Addison



Happy Saturday!

I hope you all had a fantastic week. I am happy to report that I flew to Miami and West Palm Beach, FL for the first time since Covid reared its ugly head or nearly 4 years ago when I joined my last Tribe Public (our sister organization) CEO Presentation and Q&A Luncheon event in Florida. This trip co-hosted the Tribe events with the Panna Sharma, CEO of Lantern Pharma (NASDAQ: LTRN) anti was great to see many faces of tribe members from the past and the new faces of Tribe members that chose to join us recently. This week, Starlight Therapeutics— a Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— also announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight’s clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas, brain metastases in adults, and atypical teratoid rhabdoid tumors (ATRT), and diffuse pontine glioma (DIPG) in children. In his role, Dr. Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio. Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric neurology and neuro-oncology. His experience before joining Starlight has included serving as the co-director of the neuro-oncology programs at 4 NCI designated cancer centers— Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of South Florida, and Fred Hutchinson Cancer Center at the University of Washington. He has also served as medical director for Cascadian Therapeutics, Seattle Genetics, SystImmune, Angiochem, and Pionyr Immunotherapeutics. Dr. Chamberlain has published more than 300 neurology-focused papers in peer-reviewed journals. “Starlight Therapeutics and Lantern Pharma are poised to transform oncology with AI-enabled drug development aimed at providing advanced precision therapeutics for cancers in areas of severely unmet need, such as multiple types of pediatric and adult brain cancers, for which there is currently no cure,” said Panna Sharma, CEO and President of Lantern Pharma. “Dr. Chamberlain’s insight and expertise in neuro-oncology and therapeutic development will be invaluable to the further development of treatments already in the pipeline, and the discovery and development of new future treatments that are so desperately needed by cancer patients, especially in neuro-oncology.” Dr. Chamberlain earned his medical degree at the Columbia University College of Physicians and Surgeons, followed by pediatric and neurology residencies at the University of California, Los Angeles, and a neuro-oncology fellowship at the University of California, San Francisco. “Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001″ for CNS indications), to target tumors in the brain. We are now preparing for two recurrent glioblastoma studies as part of a larger planned expansion study to assess STAR-001 in subjects who have failed standard-of-care temozolomide and involved field radiotherapy. The development of STAR-001 for use in brain tumors has utilized Lantern’s proprietary RADR® platform of in silico modeling as well as extensive preclinical experimentation in multiple in-vitro and in-vivo models,” said Dr. Chamberlain. “I’m looking forward to working alongside the talented researchers and experts at Lantern and its collaborators at Starlight who have already done so much to advance these treatments. I look forward to working together with our collaborators and clinicians to bring these and many more innovative neuro-oncology treatments to the patients who need them.” Formed in Q1 of 2023, Starlight Therapeutics is leveraging RADR®— Lantern Pharma’s proprietary artificial intelligence and machine learning platform focused on transforming the cost, pace and timeline of oncology drug discovery and development— to research, develop and clinically advance therapeutics for CNS and brain cancers.

As for the broad markets, the large caps moved up solidly with the AI theme pushing many stocks higher, however the small caps suffered over the course of the week once again. The US macroeconomic schedule provided a number of reports that led investors to recalibrate or push out their expectations that the Fed would be cutting interest rates. On Tuesday, the NY Empire State Manufacturing Index report showed a significant month over month drop to -43.7 in January. On Wednesday, the December Retail Sales report clocked in higher than expected at .6%. The Weekly MBA Mortgage Applications Index came in higher at 10.4%. the December Export Prices moved to -.9% & the December Import Prices came in flat. The December Industrial Production report came in at .1%, while the December Capacity Utilization came slightly lower at 78.6%, but steady. The November Business Inventories came in lower at -.1%, while the January NAHB Housing Market Index moved higher to 44. On Thursday, the Weekly Initial Claims report  came in lower at 187k & Weekly Continuing Claims came in lower at 1.806M. The December Housing Starts report came in higher  than expected at 1.460M, while the December Building Permits also clocked higher than expected at 1.495M, however the single-unit starts showed a 8.6% M/M drop. The January Philadelphia Fed Manufacturing Index came at -10.6. On Friday, the December Existing Home Sales report clocked in slightly below estimates at 3.78M. The Preliminary January University of Michigan Consumer Sentiment report came in at higher at 78.8.

In concert, the yield curve jumped considerably this week as the 2-yr yield rose 26bps to 4.41% and the 10-yr closed at 4.15%, up 20bps.  The U.S. Dollar Index also rose from 102.44 to 103.24. Interestingly, the CBOE Volatility Index (^VIX) rose to $13.30 from $12.70 & oil prices rose from $72.78/bbl to $73.41/bbl.

At the end of the week, the Dow 30 closed at 37,863.80 (+.7%) this week  record high and is now up .5% YTD & S&P 500 closed at 4,839.81 (+1.2%) also a record high and is now up 1.5% YTD,  The Nasdaq closed at 15,310.97 (+2.3%) and is now up 2% YTD.  

The Magnificent Seven closed as follows: Alphabet (GOOG) closing at $147.97, Amazon (AMZN) closing at $155.34, Apple (AAPL, $191.56, Meta Platforms (META) closing at $383.45, Microsoft (MSFT) closing at $367.75, NVIDIA (NVDA) closing at $594.91, & Tesla (TSLA) closing at $212.19. The small caps on the Russell 2000 closed at 1,944.39 (-.3) for the week & is now down 4.1% YTD, while the MicroCaps also moved significantly lower this week as the iShares Micro-Cap ETF (IWC) closed at $110.20 down from $111.74.

Bank stocks fell as the SPDR S&P Regional Banking ETF (KRE) dropped over the last 5-days to close at $51.03 from $51.73 and  & the SPDR S&P Bank ETF (KBE) moved down over the last 5-days to close at $45.26 from $45.67.

Overall, The Nasdaq Biotechnology ETF (IBB) closed at $135.18 down from $136.12, the NYSE ARCA Biotech Index (^BTK) closed at 5,201.97 down from 5,410.81, & the SPDR S&P Biotech ETF (XBI) closed at $87.05 from $89.30. The iShares U.S. Healthcare ETF (IYH) closed at $292.43 up from $291.56 over the last 5-days.  

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $6.28 down from $48.90 over the last 5-days.

From the world of cryptocurrency, Bitcoin (BTC) moved to 41,588.06 down from $44,061.63 over the course of the last 5-days at the time of the completion of this message.

Gold prices closed at $2,030 down from $2,049 over the last 5-days.  Silver prices closed at $22.68 down from $23.25 down  over the last 5-days. The Global X Silver ETF (SIL) closed at $25.08 down from$26.99 over the last 5-days.





VP Watchlist Updates

 
 
 
 
 
Modular Medical, Inc. (NASDAQ: MODD, $1.79, -1.10% over last 5-days and +88.42% over the last 6-months), is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
 
On Dec. 14, Seanergy announced  that the Board of Directors of the Company (“BOD”) has authorized a new $25 million buyback program (the “Plan”) which can be utilized to repurchase the Company’s common shares and other securities. The Company will also fully repay its last remaining convertible note (the “Note”) pursuant to the terms of the Note. The Note bears a 5.5% coupon, it is the last from a series of convertible notes with aggregate original notional amount of $38.7 million and $3.2 million face value remains outstanding. The full repayment of the Note will preempt potential dilution upon conversion of the Note.
 
On Dec. 21, Modular Medical announced a collaboration agreement with Glooko, Inc., a global leader specializing in connected care and remote patient monitoring for diabetes. Integrating with Glooko will allow clinicians and patients to easily review insulin dosing data from the MODD1 pump, when commercially available. In addition, through Glooko’s platform, Dexcom CGMS users will be able to view their glucose levels in the same accessible format in conjunction with their pump data. Glooko’s platform has a broad installed base, which has been deployed in over 30 countries and 8,000 clinical locations. Jeb Besser, CEO of Modular Medical stated, “We are extremely pleased to add the Glooko technology platform to our diabetes care system making it even easier and more cost effective for us to provide this important capability to our clinical and patient base. Glooko’s mission to improve health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform fits perfectly with our vision of providing an easy to use, affordable delivery technology to give more patients access to better care.”
 
 



Lantern (LTRN) closed at $4.04 and up  to 44.09 in the aftermarket on Friday. Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On Jan. 17, Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight’s clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas, brain metastases in adults, and atypical teratoid rhabdoid tumors (ATRT), and diffuse pontine glioma (DIPG) in children. In his role, Dr. Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio. Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric neurology and neuro-oncology. His experience before joining Starlight has included serving as the co-director of the neuro-oncology programs at 4 NCI designated cancer centers— Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of South Florida, and Fred Hutchinson Cancer Center at the University of Washington. He has also served as medical director for Cascadian Therapeutics, Seattle Genetics, SystImmune, Angiochem, and Pionyr Immunotherapeutics. Dr. Chamberlain has published more than 300 neurology-focused papers in peer-reviewed journals. “Starlight Therapeutics and Lantern Pharma are poised to transform oncology with AI-enabled drug development aimed at providing advanced precision therapeutics for cancers in areas of severely unmet need, such as multiple types of pediatric and adult brain cancers, for which there is currently no cure,”said Panna Sharma, CEO and President of Lantern Pharma. “Dr. Chamberlain’s insight and expertise in neuro-oncology and therapeutic development will be invaluable to the further development of treatments already in the pipeline, and the discovery and development of new future treatments that are so desperately needed by cancer patients, especially in neuro-oncology.” Dr. Chamberlain earned his medical degree at the Columbia University College of Physicians and Surgeons, followed by pediatric and neurology residencies at the University of California, Los Angeles, and a neuro-oncology fellowship at the University of California, San Francisco. “Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001″ for CNS indications), to target tumors in the brain. We are now preparing for two recurrent glioblastoma studies as part of a larger planned expansion study to assess STAR-001 in subjects who have failed standard-of-care temozolomide and involved field radiotherapy. The development of STAR-001 for use in brain tumors has utilized Lantern’s proprietary RADR® platform of in silico modeling as well as extensive preclinical experimentation in multiple in-vitro and in-vivo models,” said Dr. Chamberlain. “I’m looking forward to working alongside the talented researchers and experts at Lantern and its collaborators at Starlight who have already done so much to advance these treatments. I look forward to working together with our collaborators and clinicians to bring these and many more innovative neuro-oncology treatments to the patients who need them.” Formed in Q1 of 2023, Starlight Therapeutics is leveraging RADR®— Lantern Pharma’s proprietary artificial intelligence and machine learning platform focused on transforming the cost, pace and timeline of oncology drug discovery and development— to research, develop and clinically advance therapeutics for CNS and brain cancers.

On Nov. 30, Lantern announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements. Lantern highlighted that the Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial protection, Lantern has initiated a first-in-human Phase 1 trial (NCT06132503) for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), including high-grade B-cell lymphoma (HGBL) and mantle cell lymphoma (MCL), & this Orphan Drug Designation marks the second such designation for drug-candidate LP-284 this year.

On Nov. 8, Lantern announced operational highlights and financial results for the third quarter ended September 30, 2023 highlighting the following: 

  • Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284, a first-in-human trial for advanced, refractory non-Hodgkin’s lymphomas (NHL). 
  • Dosed initial patient in Phase 1 with LP-184, a clinical trial for multiple advanced solid tumors that are refractory to standard-of-care therapies.
  • Progressed Phase 2 LP-300 Harmonic™ clinical trial towards enrollment in East Asian countries where 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; continued expansion of additional clinical trial sites in the US and increased focus on recruitment activity with advocacy groups.
  • Developed initial proof-of-concept and preclinical evidence for a novel cryptophycin-based ADC (antibody-drug conjugate); initial data is planned to be shared in January 2024.
  • Furthered development of Lantern’s AI platform, RADR®, to include modules for the streamlined development of ADCs and the prediction of drug combinations with existing approved checkpoint inhibitors.
  • Approximately $45 million in cash, cash equivalents, and marketable securities as of September 30, 2023, is anticipated to provide a cash runway into at least Q3 of 2025.


Deckers Brands (NYSE: DECK, $749.25, +1.70% over the last 5-days & +79.70% over the last year), a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories, announced financial results recently for the second fiscal quarter ended September 30, 2023. The Company also provided an update to its financial outlook for the full fiscal year ending March 31, 2024. “The strength of demand for our HOKA and UGG brands continued to drive exceptional performance, producing record revenue and earnings for Deckers in both the second quarter and first half of fiscal year 2024,” said Dave Powers, President and Chief Executive Officer. “Our team’s ability to deliver compelling products that create emotional connections with consumers through engaging marketing campaigns, differentiates our brands in a competitive marketplace. This, paired with our strategic approach to marketplace management, led by our DTC channel, remains paramount to the success of our brands and Company. We are focused on maintaining the integrity of our healthy brands to deliver the results detailed in our increased outlook, while remaining aligned with long-term objectives.”

On Nov. 16, HOKA®, a division of Deckers Brands, introduced its latest partnership with SATISFY®, the Paris-based performance brand on a mission to help runners ‘Unlock the High.’ Together, both brands have developed a new, collaborative version of the iconic HOKA Clifton LS, the HOKA x SATISFY Clifton LS. A testament to both brand’s commitment to uncompromised performance, seamlessly integrating the HOKA brand’s trusted functionality with SATISFY’s performance design.


Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $1.80, +0.00% over the last 5-days.

Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

In pre-clinical studies tumor eradication was observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated safe i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

On Jan. 4, Indaptus announced that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections. The patent, titled “Methods of Treatment of Infections Using Bacteria,” (Application 19 866 580.4) provides protections for the application of the Company’s Decoy technology platform alone or in combination with standards of care for the prevention or treatment of any viral infection. The EPO patent will be the second patent granted to Indaptus outside the United States for this application. Jeffrey Meckler, Indaptus Therapeutics CEO, commented, “The continued protection of our intellectual property both in the U.S. and abroad will provide a competitive advantage for the Company, which should ultimately drive significant shareholder value over time. We continue to explore the applications of our technology platform beyond solid tumors, for which we are currently engaged in a Phase 1 clinical trial, and look forward to updating our shareholders on scientific progress.”

On Nov. 6, Indaptus announced interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. A broad expression of cytokines and chemokines associated with innate and adaptive anti-tumor immune responses was observed, while adverse events were generally tolerable and resolved within 30 minutes to three days. Decoy20 is designed to “re-set” the immune system’s response to cancer. The poster was presented on November 4, 2023, at the Society for Immunotherapy of Cancer in San Diego.

“We are impressed that we saw short-term induction of more than 50 cytokines, chemokines and biomarkers and believe this is unprecedented with a single agent. These early data support our long-standing hypothesis that the Decoy platform may induce robust immune responses across multiple types of immune cells that we believe are important for the eradication of solid tumors,” commented Indaptus CEO Jeffrey Meckler. Learn more here. 

Also, on Nov. 6, Indaptus announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20’s mechanism of action, and we look forward to continuing to track them. In the meantime, we have already dosed our first patient in the second cohort, for which we have titrated the dose down in anticipation of a similar response. We continue to expect to have the second cohort completed by early 2024, which would provide guidance for the selection for the recommended Phase 2 dose for subsequent multi-dosing and combination studies, which are also planned for 2024,” said Jeffrey Meckler, Chief Executive Officer of Indaptus. “We are also fortunate to be receiving the benefit of our appointment of industry veteran, Roger Waltzman, M.D., as our Chief Medical Officer, who has already proven valuable even in this short period. We anticipate continuing to benefit from his expertise as we move forward with our Phase 1 trial and further develop the Decoy platform. In the meantime, we are prudently managing our cash position.”

On Sept, 29, Tribe Public hosted a Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined” Indaptus Therapeutics’ (NASDAQ: INDP) CEO, Jeffrey Meckler delivered a presentation & also addressed a 5-10 minute Q&A session at the end of the presentation. You may view it now by clicking here. 


Learn more about Indaptus Therapeutics (NASDAQ: INDP) at the VP Watchlist page by clicking here.
 

 

 

Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $6.26, -2.03% over the last 5-days. Recently, ADT released its third quarter 2023 financial results recently and beat expectations. They highlighted the following progress: Significant balance sheet improvement driven by divestiture of commercial business, Record high CSB recurring monthly revenue balance driven by strong retention, Improved capital efficiency with record revenue payback of 2.0 years, & Continued innovation in core smart home security markets and rationalization of solar footprint.

On Oct. 2, GTCR, a leading private equity firm, announced that it has closed the acquisition of ADT’s commercial security, fire and life safety security businessfrom ADT Inc. (“ADT”, NYSE: ADT). Moving forward as a standalone organization, ADT Commercial will rebrand as Everon. GTCR will partner with former Protection1 executives Dan Bresingham and Tim Whall, along with other members of ADTC leadership, to acquire the Company, one of the leading national providers of electronic security and fire safety services to commercial enterprises and multi-site national accounts. Mr. Bresingham, former leader of ADT’s commercial security, fire and life safety business, will become Chief Executive Officer of Everon and Mr. Whall will serve as an active director on the Company’s Board.


Shares of Seanergy Maritime Holdings Corp. (SHIP), the only pure-play Capesize ship-owner publicly listed in the U.S. closed at $8, +10.80% over the last 5 days, +33.33% over the last year. Seanergy is known as a leading player in the global shipping industry, being the only pure-play Capesize ship owner publicly listed in the U.S. The company specializes in Capesize shipping, representing the largest dry bulk carriers globally. Seanergy’s operating fleet currently consists of 17 vessels (1 Newcastlemax and 16 Capesize), with an average age of approximately 12.7 years and an aggregate cargo-carrying capacity of approximately 3,054,820 deadweight tons (dwt). The company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece.

On Dec. 14, Seanergy announced that the Board of Directors of the Company (“BOD”) has authorized a new $25 million buyback program (the “Plan”) which can be utilized to repurchase the Company’s common shares and other securities. The Company will also fully repay its last remaining convertible note (the “Note”) pursuant to the terms of the Note. The Note bears a 5.5% coupon, it is the last from a series of convertible notes with aggregate original notional amount of $38.7 million and $3.2 million face value remains outstanding. The full repayment of the Note will preempt potential dilution upon conversion of the Note.


Brad Hansen CEO of Holu Hou Energy (HHE), a company that uniquely brings state-of-the-art renewable energy and energy storage systems to the Single-Family Residential, Multi-Dwelling Unit Residential, and Commercial building markets, presented at our sister organization’s Tribe Public Webinar Presentation and Q&A Event titled “Discover How Multi-Dwelling Units Are Profitably Implementing Solar Energy Today.” The event video has now been published at the Tribe Public YouTube Channel and can be view now by clicking on this link

Note that HHE was recognized as the 2023 winner of the Innovative Tech Company of the Year at the 13th annual Pacific Edge Business Achievement Awards Gala in Honolulu, Hawai’i. With operations in California, Hawai’i, Wisconsin, and Shanghai, HHE engineers proprietary storage system and control platform solutions, including a breakthrough HHE “EnergyCluster” technology that is key to the development of the Multi-Dwelling Unit Residential housing market that uniquely allows for sharing amongst local units of excess energy created by solar energy production. This technology uniquely solves the key problems for installing solar energy for MDU tenant units: tenant load variability and tenant churn. Thus, HHE is essentially good for all parties. It is a vital partner for investors and asset owners who are seeking MDU renewable energy solutions that create a new and significant multi-year revenue stream. For tenants, the adoption is non-disruptive and, in practice, allows for energy control and localized resiliency. 

On Nov. 2, Holu Hou Energy LLC announced that it is has closed a $20M construction financing facility in support of the construction of Hawaii’s largest solar and energy storage project pipeline. The funding will enable procurement of the materials and EPC resources to construct MDU projects slated for completion in the next 4-quarters. HHE’s EnergyCluster Technology has  reportedly enabled the Largest Non-Utility Solar Project Pipeline in Hawaii – Approaching $1.0 Billion in Value.

 
 
On Jan. 5, StoneCo received from the Brazilian Central Bank (“BCB”) the “Financeira” License, organized as a Sociedade de Crédito, Financiamento e Investimento (SCFI). This license will enable StoneCo, through its subsidiaries, to develop and offer a range of new products, such as time deposits, which shall enhance and diversify the funding sources of the Company.
 
On Dec. 18 StoneCo announced that it has obtained a commitment of US$467.5 million in the form of a revolving securitization facility from the United States International Development Finance Corporation (DFC), an agency of the United States government. The facility, which has a final maturity of seven years, and a six-month availability period, acquires accounts receivables due by over twenty different non-systemic important Brazilian financial institutions that are credit card issuers, on a non-recourse basis. It will further strengthen Stone’s ability to offer prepayment of receivables to micro, small, and medium-sized businesses (MSMBs), which use the solution to optimize cash flow, financial flexibility and improve management. The closing of the transaction is subject to customary conditions precedents.


INVO Bioscience, a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has recently signed a definitive merger agreement with NAYA Biosciences (“NAYA”) to establish an expanded, publicly traded life science company, announced this week that it has filed S-4 registration and preliminary joint proxy statements in connection with the upcoming merger. NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024. The additions to the board join Chairman and Chief Executive Officer Dr. Daniel Teper, Vice Chairman Dr. Peter Kash, and Director Gilles Seydoux and will continue post-merger as part of the combined company alongside current INVO CEO Steve Shum. “NAYA is thrilled to welcome new board members with outstanding executive and entrepreneurial track records,” commented NAYA CEO Dr. Daniel Teper. “As we prepare for our merger with INVO, their experience will be key in helping the management team structure our group of companies and secure financing to advance our ambitious growth strategy for 2024 and beyond. Upon closing of the merger with INVO, the NAYA leadership team will focus on scaling up the fertility business through clinic acquisitions and revamped commercialization of INVOcell®, advancing the clinical development of our oncology assets, and building our regenerative medicine portfolio.”

Naya announced on Dec. 11 that new data for its CD38-targeted Flex-NK™ Bispecific Antibody (NY-338, formerly CYT-338) for the treatment of Multiple Myeloma (MM) was published as an abstract in the 2023 American Society of Hematology’s (ASH) meeting supplement of Blood, in the “Multiple Myeloma: Prospective Therapeutic Trials” section. “NAYA is building a portfolio of differentiated clinical-stage oncology therapeutics, starting with two FLEX-NK™ bispecific antibodies acquired from Cytovia Therapeutics,” commented NAYA CEO Dr. Daniel Teper. “We are excited about this new data for our CD38-targeted antibody, which aims to address limitations with the current standard-of-care and offer new options for multiple myeloma patients.”

“The synergistic engagement of NK cells through NKp46 greatly enhances the immunotherapeutic effects of FLEX-NK™ bispecific antibodies, reducing NK cell fratricide, maintaining NK cell levels, and enhancing potency including reversal of NK cell dysfunction,” added Ola Landgren, MD, PhD, co-author of the abstract and Professor of Medicine, Chief of the Myeloma Division, and Leader of the Experimental Therapeutics Program at the University of Miami’s Sylvester Comprehensive Cancer Center. “The data supports initiation of clinical trials to evaluate this promising new therapy and makes it a potential best-in-class anti-CD38 therapeutic for multiple myeloma.”

Learn more about Naya by watching this Tribe Public video event titled “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper.


BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced this week early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again as we move forward!

Investing & Inspiration

  1. “A man should always consider how much he has more than he wants.” – Joseph Addison
  2. “Happiness is good health and a bad memory.” –  Ingrid Bergman
  3. “We pass through this world but once.” – Stephen Jay Gould
  4. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
  5. “Nothing can have value without being an object of utility.” – Karl Marx
  6. “Always turn a negative situation into a positive situation.” – Michael Jordan
  7. “Courage is found in unlikely places.” – J. R. R. Tolkien
  8. “One that would have the fruit must climb the tree.” – Thomas Fuller
  9. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
  10. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
  11. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
  12. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
  13. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
  14. “Time is money.” – Benjamin Franklin
  15. “Change before you have to.” – Jack Welch
  16. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
  17. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
  18. “Care and diligence bring luck.” – Thomas Fuller
  19. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  20. “A man who is a master of patience is master of everything else.” – George Savile
  21. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  22. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
  23. “Act as if what you do makes a difference. It does.” – William James
  24. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  25. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  26. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  27. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  28. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  29. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  30. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  31. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  32. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  33. “Action is the foundational key to all success.” – Pablo Picasso
  34. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  35. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  36. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  37. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  38. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  39. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  40. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  41. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  42. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  43. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  44. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  45. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  46. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  47. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  48. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  49. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  50. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  51. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  52. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  53. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  54. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  55. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  56. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  57. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  58. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  59. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  60. “I want to put a ding in the universe.” – Steve Jobs

  61. “Research is creating new knowledge.” – Neil Armstrong

  62. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  63. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  64. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  65. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  66. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  67. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  68. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  69. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  70. “The best way out is always through.” – Robert Frost

  71. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  72. “Without labor nothing prospers.” – Sophocles

  73. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  74. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  75. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  76. “He who is brave is free.” – Lucius Annaeus Seneca
  77. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  78. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  79. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  80. “He who knows that enough is enough will always have enough.” – Lao Tzu

  81. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  82. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  83. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  84. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  85. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  86. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  87. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  88. “Success is dependent on effort.” – Sophocles
  89. “Nobody who ever gave his best regretted it.” – George Halas
  90. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  91. “And when I breathed, my breath was lightning.” – Black Elk
  92. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  93. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  94. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  95. “We are an impossibility in an impossible universe.” – Ray Bradbury
  96. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  97. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  98. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  99. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  100. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  101. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  102. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  103. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  104. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  105. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  106. “There is more to life than increasing its speed.” – Mahatma Gandhi
  107. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  108. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  109. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  110. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  111. “Life is too short for long-term grudges.” – Elon Musk
  112. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  113. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  114. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  115. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  116. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  117. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  118. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  119. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  120. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  121. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  122. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  123. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  124. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  125. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  126. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  127. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  128. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  129. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  130. “Delete the negative; accentuate the positive!” – Donna Karan
  131. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  132. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  133. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  134. “Everything has beauty, but not everyone sees it.” – Confucius
  135. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  136. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  137. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  138. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  139. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  140. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  141. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  142. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  143. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  144. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  145. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  146. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  147. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  148. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  149. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  150. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  151. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  152. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  153. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  154. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  155. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  156. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  157. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  158. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  159. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  160. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  161. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  162. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  163. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  164. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  165. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  166. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  167. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  168. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  169. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  170. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  171. “The secret of getting ahead is getting started.” – Mark Twain
  172. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos